Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Daniel Gold sold 779,741 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $39.14, for a total value of $30,519,062.74. Following the completion of the sale, the director directly owned 911,127 shares in the company, valued at $35,661,510.78. This trade represents a 46.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Daniel Allen Gold also recently made the following trade(s):
- On Tuesday, November 17th, Daniel Gold sold 602,021 shares of Roivant Sciences stock. The shares were sold at an average price of $38.24, for a total transaction of $23,021,283.04.
Roivant Sciences Price Performance
Roivant Sciences stock opened at $38.96 on Friday. Roivant Sciences Ltd. has a 1 year low of $19.96 and a 1 year high of $42.50. The firm has a 50-day moving average of $37.22 and a two-hundred day moving average of $32.59. The stock has a market cap of $28.23 billion, a price-to-earnings ratio of -61.84 and a beta of 1.23.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, October 21st. HC Wainwright lifted their price objective on shares of Roivant Sciences from $47.00 to $48.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. UBS Group set a $55.00 price target on shares of Roivant Sciences in a research report on Wednesday, September 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 24th. Finally, Jefferies Financial Group raised their price target on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and an average target price of $46.82.
Check Out Our Latest Report on Roivant Sciences
Roivant Sciences Company Profile
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
Read More
- Five stocks we like better than Roivant Sciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
